Posted inClinical Updates news
Personalized Low-Dose Aspirin Use for Cancer Prevention in Older Adults
A secondary analysis of the ASPREE trial reveals low-dose aspirin’s heterogeneous effects on cancer prevention in older adults, highlighting clonal hematopoiesis of indeterminate potential (CHIP) as a key predictor for benefit.













